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The spread of “obesity epidemic” and the poor efficacy of many anti-obesity
therapies in the long-term highlight the need to develop novel efficacious therapy.
This necessity stimulates a large research effort to find novel mechanisms controlling
feeding and energy balance. Among these mechanisms a great deal of attention
has been attracted by a family of phospholipid-derived signaling molecules that play
an important role in the regulation of food-intake. They include N-acylethanolamines
(NAEs) and N-acylphosphatidylethanolamines (NAPEs). NAPEs have been considered
for a long time simply as phospholipid precursors of the lipid mediator NAEs, but
increasing body of evidence suggest a role in many physiological processes including
the regulation of feeding behavior. Several observations demonstrated that among
NAEs, oleoylethanolamide (OEA) acts as a satiety signal, which is generated in the
intestine, upon the ingestion of fat, and signals to the central nervous system. At
this level different neuronal pathways, including oxytocinergic, noradrenergic, and
histaminergic neurons, seem to mediate its hypophagic action. Similarly to NAEs,
NAPE (with particular reference to the N16:0 species) levels were shown to be
regulated by the fed state and this finding was initially interpreted as fluctuations
of NAE precursors. However, the observation that exogenously administered NAPEs
are able to inhibit food intake, not only in normal rats and mice but also in mice
lacking the enzyme that converts NAPEs into NAEs, supported the hypothesis of
a role of NAPE in the regulation of feeding behavior. Indirect observations suggest
that the hypophagic action of NAPEs might involve central mechanisms, although
the molecular target remains unknown. The present paper reviews the role that OEA
and NAPEs play in the mechanisms that control food intake, further supporting this
group of phospholipids as optimal candidate for the development of novel anti-obesity
treatments.
Keywords: oleoylethanolamide, N-acylphosphatidylethanolamines, oxytocin, histamine, hypothalamus, nucleus
of the solitary tract, satiety and food intake, obesity
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Oleoylethanolamide and NAPE as Lipid
Mediators
The growing prevalence of obesity and the limited
pharmacological therapies currently available to control
overfeeding of obese patients in an efficacious and safe
manner highlights the need to identify novel neuro-molecular
mechanisms involved in the control of food intake for the
development of new drugs. This research area has expanded
rapidly and led to the description of a large multitude of
neuroanatomical, neurochemical, and genetic mechanisms
(Benoit et al., 2008; Figlewicz and Sipols, 2010) organized in a
complex, redundant, and highly integrated network of several
endogenous molecules of heterogeneous nature, such as peptides,
hormones, and lipids (Matias et al., 2006; Diéguez et al., 2011;
Ghourab et al., 2011; Lateef et al., 2011; Parker and Bloom,
2012; Tsuneki et al., 2012). Within the lipid compounds a great
deal of attention has been recently dedicated to a family of
phospholipid-derived signaling molecules identified to play an
important role in the regulation of food-intake. They include
N-acylethanolamines (NAEs; Rodríguez de Fonseca et al., 2001;
Fu et al., 2007; Dipasquale et al., 2011; Piomelli, 2013; D’Addario
et al., 2014) and N-acylphosphatidylethanolamines (NAPEs;
Gillum et al., 2008).
N-acylethanolamines have been themost widely characterized.
They include anandamide that was the most studied among
them for its ability to act as endogenous cannabinoid ligand
(D’Addario et al., 2014). Besides cannabinoid receptors, it has
been gradually demonstrated that, depending on the nature of the
N-linked acyl chain, NAEs can interact with different receptors
in animals, including also vanilloid receptors and peroxisome
proliferator activated-receptors (PPAR), and to be involved in
many physiological processes (Fu et al., 2003; Nielsen et al., 2004;
Terrazzino et al., 2004; Diep et al., 2011). With regard to the role
played in the regulation of food intake, the most studied NAE was
the monounsaturated analog of anandamide, oleoylethanolamide
(OEA). Produced primarily in the small intestine, upon the
absorption of dietary fat, OEA was demonstrated to act as a
satiety signal in rodents by prolonging the interval between meals
(Fu et al., 2003; Gaetani et al., 2003; Karimian Azari et al., 2014;
Romano et al., 2014a). OEA endogenousmobilization is under the
control of the sympathetic nervous system (LoVerme et al., 2006a;
Fu et al., 2011) and is mediated by two concerted reactions. The
first one is the transfer of an oleic group from the stereospecific
numbering-1 (sn-1) position of a membrane phospholipid (for
example phosphatidylcholine) to the amine group of a second
membrane phospholipid, namely phosphatidylethanolamine (PE;
Figure 1). This reaction is catalyzed by an enzyme, which remains
to be molecularly identified, and whose N-acyltransferase
activity seems to be calcium-dependent. The products of
this reaction form a chemically heterogeneous family of N-
oleoylphosphatidylethanolamines (NOPEs), which, depending on
the specific PE precursor involved, may differ in the substituents
at sn-1 and sn-2 position of PE (Figure 1). The sn-1 position is
most often esterified by a saturated fatty acid or can contain an
alkyl or alkenyl ethermoiety; while the sn-2 position usually binds
an unsaturated or polyunsaturated fatty acid (Coulon et al., 2012).
Similar enzymatic reactions take place also during the synthesis of
otherNAEs, so that NAPEs are synthesized by acylation of the free
amine group of ethanolamine-containing glycerophospholipids
(both those containing diacyl and those containing alkenyl-acyl
bound fatty acids; Natarajan et al., 1982; Schmid et al., 1990).
This mechanism for NAEs formation was described some
time ago and suggested that NAPEs merely act as unstable
intermediate metabolites quickly converted into NAEs. However,
novel evidence suggested that rather than simply precursors to
NAEs, NAPEs can be defined as signaling lipids, able to control
important biological functions on their own (Mora et al., 2002;
Wellner et al., 2013). For example, it was recently demonstrated
that among NAPEs, N-palmitoyl-phosphatidylethanolamine
(N16:0 NAPE) can be involved in the gut-to brain axis that
regulates food intake (Gillum et al., 2008; Fu et al., 2011).
The second reaction is catalyzed by a NAPE-selective
phospholipase D (NAPE-PLD; Figure 1), which was purified and
molecularly cloned by Dr. Ueda and his collaborators (Okamoto
et al., 2004). NAPE-PLD hydrolyses different analogs of the
NAPE family with similar efficiency. Targeted deletion of the
NAPE-PLD gene (Napepld) in mice did not completely prevent
OEA endogenous synthesis, thus suggesting the existence of
redundant biosynthetic pathways (Simon and Cravatt, 2010;
Tsuboi et al., 2011).
OEA and the Control of Food Intake
The natural lipid mediator OEA contributes to the peripheral
regulation of feeding by evoking a consistent and sustained
inhibition of food intake in rats and mice, after both
intraperitoneal (i.p.) and oral administration (Rodríguez de
Fonseca et al., 2001; Fu et al., 2003; Gaetani et al., 2003; Nielsen
et al., 2004; Oveisi et al., 2004; Proulx et al., 2005; Astarita et al.,
2006; Karimian Azari et al., 2014; Romano et al., 2014a).
Rats start their feeding activity around dark onset, with a
variable latency. The activity is organized into episodes called
“meals” that can correspond to a variable amount of food eaten
(meal size). Meals are separated by intervals of variable duration
(inter-meal interval; Gaetani et al., 2003; Karimian Azari et al.,
2014; Romano et al., 2014a). Anorexic agents and feeding-
regulating hormones act by modifying different aspects of this
patterned behavior. The effect of OEA differs mechanistically
from those of the serotonergic anorexiant d-fenfluramine, which
affects both latency and meal size (Clifton et al., 2000), and
of the intestinal peptide CCK, which mostly reduces meal size
(Ritter et al., 1999). In particular, the anorexiant effect of OEA
depends on the feeding state of the rats (Gaetani et al., 2003;
Karimian Azari et al., 2014). In fact i.p. administration of OEA
(1–20 mg/kg) causes a dose-dependent delay in the feeding onset
in free feeding animals without altering the behavioral pattern
of feeding, whereas it evokes both delayed feeding onset and
reduced meal size in food-deprived rats (Gaetani et al., 2003;
Karimian Azari et al., 2014). On virtue of the variety of different
factors that can influence feeding in a non-specific manner, it
is important to underlie that OEA suppresses feeding without
causing stress, visceral illness and without affecting locomotor
activity (Rodríguez de Fonseca et al., 2001; Proulx et al., 2005).
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FIGURE 1 | The synthesis of oleoylethanolamide (OEA) is mediated
by two concerted reactions: The first one is the N-acylation of
phosphatidylethanolamine (PE) from the phospholipid bilayer of
the cell membrane, mediated by a N-acyltransferase (NAT) to
form N-oleoylphosphatidylethanolamine (NOPE) and the second
one is the phospholipase D (PLD)-mediated hydrolysis of NOPE.
Similar enzymatic reactions take place also during the synthesis of other
NAEs, so that NAPEs are synthesized by acylation of the free amine
group of ethanolamine-containing glycerophospholipids (both those
containing diacyl and those containing alkenyl-acyl bound fatty acids)
and transformed into the respective NAEs by NAPE-dependent
PLD.
Moreover the behavioral specificity of the anorexigenic effect of
OEA is further supported by the observation that OEA does
not affect drinking behavior or sodium appetite (Rodríguez de
Fonseca et al., 2001; Proulx et al., 2005). The anorexiant effect
of OEA is also structurally selective, as the endocannabinoid
anandamide, and close analogs of OEA, such as oleic acid,
linoleoylethanolamide (LEA), and palmitoylethanolamide (PEA)
are inactive or less active than OEA, when administered i.p. to
laboratory rats (Rodríguez de Fonseca et al., 2001; Hansen and
Diep, 2009; Diep et al., 2011). In particular, PEA is significantly
less potent than OEA in reducing food intake; LEA is similar in
potency to OEA and anandamide and oleic acid have no effect
(Rodríguez de Fonseca et al., 2001; Diep et al., 2011).
The endogenous levels of OEA, as well as of PEA and LEA, are
regulated by the nutritional status of the animals. In fact, fasting
decreases NAEs levels in the first tract of the small intestine,
while food ingestion stimulates cells in the mucosal layer of
the duodenum and jejunum to produce endogenous OEA (Fu
et al., 2007, 2011), PEA and LEA (Diep et al., 2011; Igarashi
et al., 2015). This observation further supports the hypothesis
that endogenous OEA might participate to the induction of
satiety (Dipasquale et al., 2011; Piomelli, 2013). In support
of this idea, the enhancement of food-stimulated mobilization
of OEA in the intestine, obtained by a viral-vector-mediated
overexpression of NAPE-PLD into the duodenum of rats, elicits
a satiety effect behaviorally similar to that observed after the
systemic administration of exogenous OEA (Fu et al., 2008). This
evidence further points to the role of endogenous OEA in the
small intestine as a local satiety messenger.
Moreover, the observation that the endogenous levels of
intestinal OEA, LEA and PEA can be affected by the fat content
of the diet in a time- and dose-dependent manner, suggested a
possible role of these anorexiant NAEs as intestinal fat sensor
(Diep et al., 2011). This hypothesis is further supported by the
recent finding that suchmechanism is altered in animals rendered
obese by the exposure to a high fat diet or in animals fed with a
high-sucrose low-fat diet, in which OEA and LEA mobilizations
from the intestine do not respond to the intraduodenal infusion
of lipids (Igarashi et al., 2015). These observations suggest that
alterations of the anorexiant NAE pathways might contribute to
hyperphagia and to the development of obesity.
Peroxisome Proliferator-activated
Receptor (PPAR)-alpha Mediates the
Satiety-inducing Effects of OEA
Several lines of evidences indicate that OEA is a high-affinity
agonist of the nuclear PPAR-alpha, the molecular target of the
antihyperlipidemic drugs fibrates, whereas it does not engage
PPAR-gamma or retinoid-X receptor—a functional partner in
PPAR-activated transcription (Fu et al., 2003). OEA is a more
potent activator of PPAR-alpha (EC50 = 120 nM) compared to
other natural ligands, such as oleic acid (EC50 = 10 mM) and
synthetic agonists, such as GW7647 (EC50 = 150 nM) (Fu et al.,
2003; Lo Verme et al., 2005a). Saturation binding experiments
show that OEA binds to the purified ligand-binding (LBD)
domain of PPAR-alpha with a KD of approximately 40 nM (Fu
et al., 2003; Lo Verme et al., 2005b). Furthermore, experiments in
genetically modifiedmice show that OEA does not reduce feeding
in animals lacking a functional PPAR-alpha gene, suggesting that
PPAR-alpha activation crucially contributes to the hypophagic
actions of OEA (Fu et al., 2003; Lo Verme et al., 2005b). In
support of the selectivity of such effect, PPAR-alpha deficient
mice retain the ability to respond to other anorexiant agent,
such as d-fenfluramine and cholecystokinin (Fu et al., 2003).
Moreover PPAR-alpha deficient mice show decreased eating
latency and increased feeding frequency, without other alterations
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of ingestive behavior (Schwartz et al., 2008). The possibility that
OEA evokes hypophagia by activating PPAR-alpha is further
supported by several findings: (i) the two potent synthetic PPAR-
alpha agonists GW7647 and Wy-14643 inhibit food intake, while
fibrates, which are weak PPAR-alpha agonists (Kersten andWahli,
2000), have no anorexiant effect; (ii) the administration of OEA
or synthetic PPAR-alpha agonists alter the expression of PPAR-
alpha -regulated genes in the small intestine and liver (Fu et al.,
2003); (iii) food intake increases OEA concentrations in the
intestinal mucosa to levels (300 nM) that are sufficient to fully
activate PPAR-alpha (Fu et al., 2007, 2011). Moreover, PPAR-
alpha activation induces several transcriptional changes that lead
to an increase of fatty-acid catabolism, a reduction of blood lipid
levels and a decrease of body-weight gain (Willson et al., 2000;
Berger and Moller, 2002): the chronic treatment with OEA in
rodent models of obesity can produce all these effects (Rodríguez
de Fonseca et al., 2001; Fu et al., 2005).
Besides PPAR-alpha receptor, other molecular targets have
been proposed to mediate OEA’s actions in vivo (Dipasquale
et al., 2011; Piomelli, 2013). These include the transient receptor
potential cation channel vanilloid-1 (TRPV1) and the “orphan”
G-coupling receptor, GPR119. The evidence supporting the
interaction with the TRPV1 came from few studies. The first
one was performed on Xenopus oocytes and showed that OEA
can activate this receptor (with an EC50 of approximately 2 mM)
once it has been phosphorylated by protein kinase C (PKC;
Ahern, 2003). The second study demonstrated that OEA is able to
depolarize capsaicin-sensitive nodose ganglion neurons cultured
from wild type (wt) mice by evoking inward currents that can be
blocked by the TRPV1 inhibitor, capsazepine, while no response
to OEA was observed in neurons cultured from TRPV1-null
mice (Wang et al., 2005). In the same study, authors showed that
OEA administration induced visceral pain-related behaviors in wt
mice, but not in TRPV1-null animals or in wt mice pre-treated
with capsazepine (Wang et al., 2005). Similar observations were
reported also by LoVerme et al. (2006b) showing that intraplantar
administration of OEA (50 mg) into the hind paw can elicit
nocifensive behavior in wt, but not in TRPV1-null mice.
Moreover, OEA was suggested to act also as a medium-
potency (EC50 3mM) endogenous ligand of the orphan receptor
GPR119, a G protein-coupled receptor expressed predominantly
in the human and rodent pancreas and gastrointestinal tract and
also in rodent brain (Overton et al., 2006). Through the activation
of this receptor, OEA was shown to increases GLP-1 secretion
from intestinal L-cells (Lauffer et al., 2009).
However, despite these observations on OEA actions at other
possible pharmacological targets different from PPAR-alpha, it
is noteworthy that the genetic deletion of either TRPV1 or
GPR119 inmice does not prevent the anorexigenic effects of OEA,
thus clearly indicating that the activation of these two receptors
induced by OEA is not crucial for its action as a satiety signal (Lo
Verme et al., 2005b; Lan et al., 2009).
NAPE and the Control of Food Intake
N-acylphosphatidylethanolamines were observed in several
tissues and organs, including the nervous system, the
gastrointestinal tract, testis, spleen, plasma, and lymph (for
review, see Coulon et al., 2012). Within the rat nervous system
they are particularly abundant in the spinal cord (Yang et al.,
1999) and the brain stem (Bisogno et al., 1999), with a N-acyl
moiety that mostly includes N16:0, N18:0, N18:1 (69.6 17%, 12.2
3.3%, 8.1 2.5% respectively) with only a 0.2% of N20:4 (Sugiura
et al., 1996).
N-acylphosphatidylethanolamine intestinal, plasma and lymph
levels can be significantly affected by the fed state of the animals.
In fact, most NAPE species (N16:0, N 18:0, N18:1, N18:2) resulted
significantly reduced in the intestines of fasted rats and increased
within few hours upon re-feeding; the N 20:4 NAPE is the only
species showing an opposite trend (Petersen et al., 2006; Fu et al.,
2007). Such fluctuations were initially linked to the regulation of
NAE synthesis (Hansen et al., 2000). However, in 2008 Gillum
et al. (2008) proposed, for the first time, thatNAPE per se can act as
a phospholipid hormone involved in the regulation of food intake.
In particular, after confirming the previous findings showing that
in fasted rats fed with a high fat diet or subjected to intraduodenal
lipid infusion NAPE levels increased in plasma, lymph and small
intestine, they demonstrated that the exogenous administration
of the most abundant plasma NAPE (N 16:0) decreased food
intake in rats and mice after both i.p. and intracerebroventricular
(i.c.v.) administration, without causing conditioned taste aversion
(Gillum et al., 2008).
It is worth noting that N 16:0 NAPE tested in Gillum’s
experiment is not OEA precursor. The molecular target of NAPE
that ismediating its effect on food intake remains to be discovered.
It likely does not involve cannabinoid CB1 receptor, as exogenous
NAPE was still effective in suppressing food intake in CB1
knockout mice (Gillum et al., 2008). Moreover, as demonstrated
by another research group, the anorectic effects of NAPE does
not seem to be mediated by a NAPE metabolite, such as NAE, as
suggested by the observation that the hypophagic action of NAPE
can be still observed in mice lacking NAPE-PLD that are unable
to convert NAPE into NAE (Wellner et al., 2011).
However, NAPE i.p. administered can exerts its effect at large
dosage (100–200 mg/kg), and several other phospholipids have
an anorectic effect in the same dose range, when administered
i.p. (Wellner et al., 2011). This aspect raised doubts about the
specificity of NAPE anorexiant effect (Gillum et al., 2008; Wellner
et al., 2011) and questioned the suitability of the i.p. route of
administration for a large dose of this compound. Future studies
should clarify whether NAPEs and NAEs can act as independent,
possibly complementary lipid signals involved in the regulation of
food intake.
Effects Produced by OEA in the Central
Nervous System
Similarly to other anorexigenic gut-derived signals, peripherally
administered OEA (10 mg/kg i.p.) activates c-fos transcription
(investigated as marker of neuronal activation) in the nucleus
of solitary tract (NST; Rodríguez de Fonseca et al., 2001;
Gaetani et al., 2010; Romano et al., 2013, 2014b), and the
paraventricular (PVN) and supraoptic (SON) nuclei of the
hypothalamus (Rodríguez de Fonseca et al., 2001; Gaetani
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FIGURE 2 | OEA activates PPAR-alpha receptor in the proximal
small intestine (1) generating an input that induces several
transcriptional changes leading to an increase of fatty-acid
catabolism, a reduction of blood lipid levels and a decrease of
body-weight gain. The signal travels (through a mechanism that still
needs to be elucidated) to the brainstem (2), in the nucleus of solitary tract
(NST). Circulating OEA might reach the area postrema (AP; a
circumventricular organ that lacks a functional blood brain barrier and is in
strict contact with the NST). From the noradrenergic neurons within the
NST the signal reaches the oxytocinergic neurons of the paraventricular
nucleus (PVN) and supraoptic nucleus (SON), where it stimulates oxytocin
expression and release, presumably the tuberomamillary nucleus (TMN) as
well, where it stimulates histamine release from neurons projecting to the
PVN (3). Oxytocin released from neurons of PVN and SON can act centrally
to modulate feeding behavior and can be released into the blood stream
from the neurohypophysis.
et al., 2010; Romano et al., 2013, 2014b). In both hypothalamic
nuclei, OEA increases c-fos mRNA and protein expression
in oxytocin-immunoreactive neurons (Gaetani et al., 2010;
Provensi et al., 2014). This activation is paralleled by increased
oxytocin mRNA levels, increased peptide neurosecretion,
and elevated circulating oxytocin levels (Gaetani et al., 2010;
Romano et al., 2013). Moreover, pharmacological blockade of
oxytocin receptors in the brain by i.c.v. infusion of the selective
oxytocin antagonist, L-368,899, prevented the anorexic effects
of OEA, suggesting that OEA suppresses feeding by activating
central oxytocinergic transmission (Figure 2; Gaetani et al.,
2010).
We recently reported that OEA requires the integrity of the
brain histaminergic system to fully exert its hypophagic effect
(Provensi et al., 2014). Brain histamine has long been known as a
mediator of satiety through activation of hypothalamic histamine
H1 receptors (reviewed, in Passani et al., 2011). We found that
in mice deficient of the histamine synthesizing enzyme histidine
decarboxylase (HDC), or acutely depleted of histamine by i.c.v.
infusions of the HDC blocker a-fluoromethylhistidine, the effect
of exogenously administered OEA was significantly attenuated.
Furthermore,OEA increased c-fos expression in oxytocin neurons
of the PVN of wt, but not HDC-KO mice, suggesting that
oxytocin rich nuclei are the likely brain region where histamine
influences the central, indirect effects of OEA. In addition, i.p.
injections of OEA increased cortical release of histamine as
measured by in vivo-microdialysis in fasted mice within a time
frame that is compatible with its anorexic effect (Provensi et al.,
2014). This observation further supports the hypothesis that
histamine signaling is involved in the acute effects of OEA on food
consumption (Figure 2). Moreover, in a recent report (Romano
et al., 2014b) we showed that i.p. administration of OEA, at a
dose and at a time-point that causes a significant inhibition of
eating, stimulates c-fos transcription in specific subnuclei of the
brainstem. In particular, OEA evoked a strong signal in the area
postrema (AP), a circumventricular organ that lacks a functional
blood brain barrier, and in the medial and central part of the NST.
Interestingly, within the central part of the NST, the induction of
c-fos mRNA was more evident at the most rostral level where this
nucleus is more in contact with the AP (Romano et al., 2014b).
This observationmight suggest a direct action of OEA in the brain
stem by reaching circumventricular organs from the blood stream
(Figure 2).
Noradrenergic projections from the NST to the hypothalamus
seem to mediate OEA effects on feeding behavior and on
hypothalamic oxytocin increase (Figure 2), as demonstrated in
rats subjected to the intra-PVN administration of the toxin
saporin (DSAP) conjugated to an antibody against dopamine-b-
hydroxylase (DBH) to destroy hindbrain noradrenergic neurons
(Romano et al., 2013). In fact, in these rats the lesion induced
by DSAP administration completely prevented OEA effect on
food intake and on both c-fos and oxytocin expression in the
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PVN, thus supporting the hypothesis of a necessary role played
by the NST-PVN noradrenergic pathway (Romano et al., 2013).
In accordance with this observation, peripheral administration of
OEA (5–20mg/kg) to rats increased noradrenaline concentrations
in the hypothalamus in a dose-dependent manner (Serrano
et al., 2011). In the same study authors demonstrated also that
peripherally administeredOEAwas able to increase hypothalamic
dopamine concentrations, but failed to affect the levels of two
orexigenic neuropeptides expressed by the arcuate nucleus, such
as neuropeptide Y (NPY) or Agouti related-peptide (AgRP), in
both 24-h food derived and free-feeding rats (Serrano et al.,
2011). A positive effect of OEA was, instead, observed on the
levels of the anorexigenic peptide Cocaine and Amphetamine
Regulated Transcript (CART) in the PVN but not the arcuate
nucleus (Serrano et al., 2011).
The observation that OEA is able to affect monoaminergic
transmission in the brain was also reported by other groups.
For example, Yu et al. (2015) detected changes in cerebral
noradrenaline and serotonin levels following OEA repeated oral
administration and linked such effect to the antidepressant-like
effect produced in the same animals. Murillo-Rodríguez et al.
(2011) locally administered OEA into the lateral hypothalamus
or the dorsal raphe of rats and observed, by brain microdialysis
of the nucleus accumbens, an increase of dopamine extracellular
levels. A modulation of dopaminergic function was reported
also by other authors who demonstrated the ability of OEA to
modulate nicotinic receptors containing b2 subunits (indicated as
b2*-nAChRs) expressed by dopamine neurons that play a key role
in the reward system (Melis et al., 2013). Both observations might
suggest a role of OEA in the modulation of reward functions.
Such hypothesis was confirmed by Tellez et al. (2013), who used
OEAsubchronic treatments to re-establish a normally functioning
reward system in rats that were chronically exposed to a high fat
diet. Altogether these reports suggest that the modulation of food
intake induced by OEAmight not only affect homeostatic systems
that control hunger and satiety in the brain, but also, hedonic
and non-homeostatic aspect related to the salience of food-related
stimuli.
The vagus nerve has been shown to mediate the anorexiant
effect of NAE-related compounds (Rodríguez de Fonseca et al.,
2001). Total subdiaphragmatic vagotomy (TVX), as well as
capsaicin pre-treatment prevented the satiety effect of OEA,
which prompted the interpretation that OEA’s effect on eating
is mediated by vagal sensory fibers (Rodríguez de Fonseca
et al., 2001; Fu et al., 2003). Recently, by using a more specific
subdiaphragmatic vagal de-afferentiation (SDA), a surgery that
eliminates all abdominal vagal afferents sparing approximately
half of the efferents (Norgren and Smith, 1994; Walls et al.,
1995), we have demonstrated that OEA did not require intact
abdominal vagal afferents to reduce food intake (Karimian Azari
et al., 2014).
Effects Produced by NAPE in the Central
Nervous System
The initial evidence that NAPEs’ biological functions might
include also actions in the central nervous system (CNS) came
from in vitro studies on the cytoprotective role of NAPE in
different models of neurotoxicity or neurodegeneration (for
review, see Coulon et al., 2012). NAPE levels in the brain (aswell as
in other tissues) increase strongly in response to stress conditions
that cause a dramatic rise of intracellular calcium concentration.
This phenomenon has been linked to the calcium-dependent
acyl-transferase activity of the enzymatic reaction that leads to
the synthesis of NAPEs from membrane phospholipid precursors
(Coulon et al., 2012).
Whether similar mechanisms are involved in the effects of
NAPE on food intake remained unexplored. That the hypophagic
actions of NAPEs might be mediated by the direct interaction
with CNS targets was suggested by different observations made
by Gillum et al. (2008). In particular, they found that the
surgical elimination of nervous afferents to the brain from the
gastrointestinal tract, obtained by subdiaphragmatic vagotomy,
did not block the anorectic effects of NAPE; (i) NAPE exerted its
anorexiant effect after both central and systemic administration;
(ii) intravenously administered 14C-labeled C16:0 NAPE entered
the brain, and preferentially accumulated in the hypothalamus;
(iii) NAPE administration significantly increased c-fos expression
in the PVN and SON and decreased c-fos expression in NPY
neurons of the arcuate nucleus, with respect to fasted animals that
did not receive the drug. These latter effects strongly resemble
those produced byOEA. Therefore, the possibility that theymight
be induced by a NAPEmetabolite rather than NAPE per se cannot
be excluded.
N-acylphosphatidylethanolamine effects are not mediated
by other signals affecting food intake, such as leptin or
melanocortins. In fact, both ob/ob mice and mice lacking the
melanocortin four receptor exhibited a full anorexigenic response
to the systemic administration of NAPE and even trended toward
enhanced sensitivity (Gillum et al., 2008; Srisai et al., 2011).
Despite these initial observations future studies are necessary
to unveil the central target of NAPEs and to further explore their
biological role in the CNS.
Conclusions
The “NAE/NAPE pathway,” including the enzymes synthetizing
and degrading NAEs, their precursors and their receptors,
represents a crucial regulatory pathway for many physiological
functions and may become the target for the development
of novel therapeutic drugs for many pathological conditions.
In this review, we outlined recent progress in the studies
of the mechanisms mediating the anorexic effects of OEA
and NAPEs. Among NAEs, OEA may represent the optimal
candidate for the development of anti-obesity treatments and
NAPEs continue to be an intriguing and interesting group
of phospholipids, both as NAE precursors and in their own
right.
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